ArticleTheranostics2025

CD19-targeted HSP90 inhibitor nanoparticle combined with TKIs reduces tumor burden and enhances T-cell immunity in murine B-cell malignancies.

Mengting Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.